2025 Biotech Markets & Immuno-Oncology Outlook
Update: 2025-06-25
Description
Summary:
Mizuho Securities Analyst, Dr Graig Suvannavejh, joined the 2025 Immuno-Oncology 360º Summit to share an outlook on the IO biotech market, high-level thoughts on the IO space, and public IO company case studies to illustrate the market's perception of what's happening in IO.
More specifically:
For more information, visit IO360summit.com
Mizuho Securities Analyst, Dr Graig Suvannavejh, joined the 2025 Immuno-Oncology 360º Summit to share an outlook on the IO biotech market, high-level thoughts on the IO space, and public IO company case studies to illustrate the market's perception of what's happening in IO.
More specifically:
- The current tailwinds working for and headwinds working against investment in biotech
- The increasing specialization of investors and lack of generalist investors
- The impacts of challenging and/or disappointing readouts after the first wave of checkpoint inhibitors
- Where investors are more positive on biotech, and reasons for optimism in coming pipelines
For more information, visit IO360summit.com
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
